SecBot SecBot
6-K ·Filed Aug 6, 2026

GMAB

GENMAB A/S
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001434265-26-000108
Notable filing: 6-K
Actionable Insight ▲ Bullish

The raised guidance and strong royalty growth confirm the core business momentum, but the $5.1B debt overhang and declining net profit cap the upside. Watch for Rina-S and petosemtamab Phase 3 data readouts as key catalysts; the AbbVie trade secret litigation resuming in district court is a medium-term risk.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

GMAB drug pipeline →

rinatabart sesutecan

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3
Time to market
Regulatory submission discussions are underway following positive Phase 3 data. If filed in 2026-2027, potential FDA approval could come in 2027-2028, though the timeline depends on regulatory interactions and whether accelerated pathways are pursued.
Next catalyst
None dated

What to watchThe Phase 3 RAINFOL-02 readout (Oct 23, 2026) was a major derisking event for Rina-S with highly compelling efficacy data. Watch the October 28 investor update for regulatory filing timelines and commercial opportunity sizing. The stock is near its 52-week high with strong technical momentum but RSI overbought at 78, near-term pullback risk exists after the recent run-up.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$29.83
T+0 close · Aug 6, 2026 · via day close
Latest settled
+91.28%
T+60 · $57.06
Vs SPY
+92.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $29.83entry
  2. T+1 · 3mo ago +4.76%α +4.15% · $31.25
  3. T+5 · 3mo ago +5.06%α +3.85% · $31.34
  4. T+20 · 3mo ago +15.35%α +14.75% · $34.41
  5. T+60 · 18d ago +91.28%α +92.95% · $57.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab reported strong H1 2026 results with revenue up 25% YoY to $2,051M, driven by DARZALEX and Kesimpta royalties and EPKINLY sales. The company raised its full-year 2026 revenue guidance to $4.325-4.525B (from $4.065-4.395B) and adjusted operating profit guidance to $1.065-1.385B (from $0.900-1.400B). Positive Phase 3 data for epcoritamab in DLBCL and progress on Rina-S and petosemtamab support the pipeline, but net profit declined to $356M from $531M due to higher interest expense from the Merus acquisition debt and increased operating costs.

Key Facts

  • Revenue increased 25% YoY to $2,051M for H1 2026.
  • Full-year 2026 revenue guidance raised to $4.325-4.525B (midpoint $4.425B).
  • Full-year 2026 adjusted operating profit guidance raised to $1.065-1.385B (midpoint $1.225B).
  • DARZALEX royalties rose 20% to $1,306M; Kesimpta royalties rose 31% to $259M.
  • EPKINLY/TEPKINLY global net sales grew 48% to $312M.
  • Phase 3 EPCORE DLBCL-4 trial for epcoritamab met primary endpoint (improved PFS).
  • Net profit declined to $356M from $531M due to $217M in interest/amortization expense on borrowings.
  • Debt of $5.135B remains from the Merus acquisition; Term B Loan interest margin reduced from 3.00% to 2.00%.

Financial Impact

Revenue up 25% to $2,051M; net profit down 33% to $356M; guidance raised by ~$195M at midpoint for revenue and ~$75M for adjusted operating profit.

revenuenet profitguidancedebtroyalty revenue

Risk Factors

  • $5.1B debt from Merus acquisition creates interest expense drag on net profit.
  • AbbVie trade secret litigation over Rina-S could resume in district court after ITC withdrawal.
  • Chugai patent infringement complaint in Japan over EPKINLY poses potential sales disruption.
  • High operating expense growth (28% adjusted) may pressure margins if revenue growth slows.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000108
Document: 0001434265-26-000108-index-headers.html0001434265-26-000108
Document: 0001434265-26-000108-index.html0001434265-26-000108
Document: 0001434265-26-000108.txt0001434265-26-000108

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026